In a larger- scaled cohort study with participants without preexisting hypertension in the Prevention of Renal and Vascular End-stage Disease (PREVENT), followed-up for 10.7 years, PON1 arylesterase activity was not associated with future risk of hypertension, even though there is an inverse and independent correlation between hypertension risk and HDL-C, not modified by PON1 [28]. Here, PON1 is linked to hypertensive disorder.